# Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

> **NCT00267306** · PHASE1,PHASE2 · COMPLETED · sponsor: **Facet Biotech** · enrollment: 144 (—)

## Conditions studied

- Severe Ulcerative Colitis

## Interventions

- **DRUG:** Visilizumab

## Key facts

- **NCT ID:** NCT00267306
- **Lead sponsor:** Facet Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 144 (—)
- **Last updated:** 2012-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267306, "Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00267306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*